Updates on Immune Checkpoint Blockade Resistant Melanoma
Yana Najjar, MD
Assistant Professor of Medicine
UPMC Hillman Cancer Center
Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced melanoma, it is time to reflect on the lessons learned regarding modulation of the immune system to treat melanoma and on novel approaches to further extend the efficacy of current and emerging immunotherapies.